US 2019/0243945 A1Published application

Leveraging Genomic, Phenotypic and Pharmacological Data to Cure Disease

OwnerRichard Postrelinventor

Life of this patent

Estimating the term…

Loading patent…

Abstract

The present invention provides a process and method for repurposing existing compounds by leveraging genomic, phenotypic and pharmacological data to cure disease. Applying advanced mathematical analytics using massively interconnected computing capabilities to identify target rich sets of existing compounds available for animal testing at the earliest stage in the process collapses cycle time of development, dramatically reducing costs. Target rich sets obtained through this invention produce compounds or compositions which each have a demonstrated ability to modulate disease or an associated phenotypic expression. By rendering the mechanism of action irrelevant, this invention collapses the time and cost to discovery of an efficacious drug from decades to days and from $Billions to $Millions.

Claims24

Dependent claims

A method of identifying a compound that modulates at least one of a group of diseases, said method comprising:

a. selecting a symptom or disease;
b. feeding said symptom or disease into a search field of a structured database;
c. querying said at least one structured database for content of one or a plurality of records referencing said first symptom;
d. selecting at least one record referencing said first symptom;
e. correlating said first symptom with at least one recorded feature of said at least one record;
f. querying at least one structured database for content of one or a plurality of records referencing said at least one recorded feature;
g. listing one or more compounds and/or compositions related to controlling or attempting to control at least one symptom noted as a recorded feature in said one or a plurality of records referencing said at least one recorded feature;
h. identifying in said listing, and delisting compounds and/or compositions, if any, known to have been applied to controlling said at least one symptom;
and:
i. delivering to a physical, chemical and/or biomodel at least one said one or more compounds and/or compositions, said at least one said one or more compounds and/or compositions listed in g and remaining after h;
j. determining effect of said one or more compounds and/or compositions;
k. selecting one or more compounds and/or compositions determined to have desired effect;
and
l. identifying at least one of one or more compounds and/or compositions selected in l as said new pharmaceutical composition;
or:
j. selecting at least one alternate compound or composition, at least one of said compounds and/or compositions delisted in h;
k. optionally noting one or more undesired outcome(s), if any, resulting from said at least one alternate compound or composition being applied to controlling said at least one symptom;
l. selecting at least a second compound or composition, said at least one second compound or composition selected to contribute modulation of an activity selected from the group consisting of:
countering said one or more undesired outcome(s) (optionally, if any), anti-oxidation, anti-inflammation, diuresis, anti-diureses, anti-depression, hypertension, hypotension, naturesis, anti-naturesis, kalesis, anti-kalesis, mitochondrial fission, mitochondrial fusion, mitochondrial motility, ROS damage, O2 consumption and interferon production;
m. confirming desired activity of said at least one second compound or composition;
and
n. identifying as said new pharmaceutical composition, a composition comprising at least one said alternate compound to be used in conjunction with at least one said second compound said one or more compounds and/or compositions.

19 more elements

A method for identifying a new pharmaceutical composition for treating a disease, said method comprising:

a. selecting a first symptom of a first disease;
b. providing an identification of said first disease;
c. accessing at least one structured database;
d. querying said at least one structured database for content of one or a plurality of records referencing said first symptom;
e. selecting at least one record referencing said first symptom;
f. correlating said first symptom with at least one recorded feature of said at least one record;
g. querying at least one structured database for content of one or a plurality of records referencing said at least one recorded feature;
h. listing one or more compounds and/or compositions related to controlling or attempting to control at least one symptom noted as a recorded feature in said one or a plurality of records referencing said at least one recorded feature;
i. identifying in said listing, and delisting compounds and/or compositions, if any, known to have been applied to controlling said at least one symptom;
and:
j. delivering to a physical, chemical and/or bio model at least one said one or more compounds and/or compositions, said at least one said one or more compounds and/or compositions listed in h and remaining after i;
k. determining effect of said one or more compounds and/or compositions;
l. selecting one or more compounds and/or compositions determined to have desired effect;
and
m. identifying at least one of one or more compounds and/or compositions selected in l as said new pharmaceutical composition;
or:
j. selecting at least one alternate compound or composition, at least one of said compounds and/or compositions delisted in i;
k. optionally noting one or more undesired outcome(s), if any, resulting from said at least one alternate compound or composition being applied to controlling said at least one symptom;
l. selecting at least a second compound or composition, said at least one second compound or composition selected to contribute modulation of an activity selected from the group consisting of:
a compound countering said one or more undesired outcome(s) (optionally, if any), anti-oxidation, anti-inflammation, diuresis, anti-diureses, anti-depression, hypertension, hypotension, naturesis, anti-naturesis, kalesis, anti-kalesis, mitochondrial fission, mitochondrial fusion, mitochondrial motility, ROS damage, O2 consumption and interferon production;
m. confirming desired activity of said at least one second compound or composition;
and
n. identifying as said new pharmaceutical composition, a composition comprising at least one said alternate compound to be used in conjunction with at least one said second compound said one or more compounds and/or compositions.

20 more elements

A method for producing a new pharmaceutical composition, said method comprising:

a. selecting a first symptom of a first disease;
b. providing an identification of said first disease;
c. accessing at least one structured database;
d. querying said at least one structured database for content of one or a plurality of records selected from the group consisting of:
record(s) referencing said first symptom and record(s) referencing said first disease;
e. selecting at least one first record obtained from d;
f. selecting at least one chemical compound relating to said at least one first record;
g. querying at least one structured database for content of one or a plurality of records referencing said at least one chemical compound to obtain a listing comprising diseases and symptoms relating to said compound;
h. querying at least one structured database with results of said listing obtained from the query in g to obtain a compilation of compounds associated with symptoms or diseases of said listing;
i. analyzing compounds related in f. and h. for similarities and distinctions;
j. querying at least one structured database for negative assessments of compounds related in f. and h.;
k. correlating negative assessments with similarities and distinctions of i.;
l. associating chemical structure with said similarities and distinctions;
m. selecting chemical structural features minimizing said negative assessments;
n. designing a chimeric compound or a library of chimeric compounds maintaining at least one feature of at least one compound related in f. and h. while discarding one or more chemical feature selected in m.;
and
o. producing at least one compound designed in n.

14 more elements

Dependencies are inferred from the claim text.

Facts

Application: 15/954,575Filed 16 Apr 2018
Priority: 2 Feb 2018
Published: 8 Aug 2019
Term ends: Not estimatedThe source records don’t support an estimate.

Classification23 codes

G16C 20/40
Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds…
A61K 31/658
Medicinal preparations containing organic active ingredients: o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or…
C40B 30/00
Methods of screening libraries
G01N 33/5008
Involving human or animal cells: for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics

Family

Application62/625,962Us provisional application · filed 2 Feb 2018
US 11,468,973 B2Related patent
US 2019/0243945 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key